Stock AnalizAtriCure, Inc. ATRC
Medical/Dental Instruments · IPO 2005 · data as of November 13, 2026
AtriCure, Inc. (ATRC) is a healthcare company listed in the US with a market value of about $2.9B. In the twelve months to September 30, 2026 it had revenue of $590M and net income of $15M, a net margin of 2.5%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 189.5, a price to free cash flow of 54.7, 5-year revenue growth of 21% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $590M | $535M | $465M | $399M | $330M | $274M | $207M | $231M | $202M | $175M | $155M |
| Net income | $15M | -$11M | -$45M | -$30M | -$46M | $50M | -$48M | -$35M | -$21M | -$27M | -$33M |
| Free cash flow | $53M | $48M | $745000 | -$8M | -$39M | -$24M | -$25M | -$28M | -$10M | -$15M | -$23M |
| EPS (diluted) | $0.30 | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 | $-1.14 | $-0.94 | $-0.62 | $-0.83 | $-1.05 |
| Net margin | 2.5% | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% | -15.2% | -10.5% | -15.4% | -21.5% |
| ROIC | — | -1.3% | -5.9% | -4.0% | -6.4% | 10.0% | -7.4% | -8.4% | -4.5% | -9.9% | -11.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $64.89, 14% above the current price; targets range from $50.00 to $70.00; the consensus rating is “Buy”; expected EPS is $0.43 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is AtriCure’s P/E ratio?
About 189.5, based on the last twelve months of diluted earnings per share (forward P/E about 172.1).
Is AtriCure stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does AtriCure pay a dividend?
Not currently.
Is AtriCure a good stock to buy?
We do not give buy or sell advice. AtriCure scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.